Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
JERSEY, Channel Islands , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray.
View HTML
Toggle Summary Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland , today announced that the Company will participate in two upcoming virtual investor conferences.
View HTML
Toggle Summary Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020 European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark submission in Q4
View HTML
Toggle Summary Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020 .
View HTML
Toggle Summary Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody test
JERSEY, Channel Islands, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland , today announced that on September 25, 2020 , the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody
View HTML
Toggle Summary Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 20,294,117 ordinary shares at a price to the public of $4.25
View HTML
Toggle Summary Quotient Limited Announces Upsize and Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.  The Company is offering 17,647,059 ordinary shares at a price to
View HTML
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares.
View HTML
Toggle Summary Quotient Limited and Ortho Clinical Diagnostics Settle Arbitration and Sign Binding Letter of Intent Covering Patient Transfusion Diagnostics
JERSEY, Channel Islands, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland , today announced that the Company and Ortho Clinical Diagnostics (Ortho) have signed a binding letter of intent that confirms the termination of their former
View HTML
Toggle Summary Bloodworks Northwest Now Tests All Donors for COVID-19 Antibodies Looking for More Qualified Convalescent Plasma Donors
Testing Conducted Using the Highly Accurate MosaiQ COVID-19 Antibody Test from Quotient JERSEY, Channel Islands, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Bloodworks Northwest is now offering all blood donors across the Pacific Northwest free COVID-19 antibody testing with the possibility of discovering
View HTML